Drug-induced severe cutaneous adverse reactions in a patient after COVID-19 infection. Case report
Article Sidebar
Main Article Content
Abstract
During the COVID-19 pandemic, various adverse drug reactions were observed. This could have been related to a greater immunological susceptibility of patients with SARS-CoV-2 to present this type of symptoms, as well as exposure to multiple drugs used in their treatment. We report the case of a patient with a severe respiratory infection due to COVID-19, who presented 2 serious adverse drug reactions associated with paracetamol in a short period of time.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Phelan AL, Katz R, Gostin LO. The Novel Coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323(8):709-710. https://doi.org/10.1001/jama.2020.1097. DOI: https://doi.org/10.1001/jama.2020.1097
Emadi SN, Hamzelou S, Saffarian Z, et al. Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: a case report. Dermatol Ther. 2021;34(1):e14656. https://doi.org/10.1111/dth.14656. DOI: https://doi.org/10.1111/dth.14656
Herrera-Lasso Regás V, Dordal Culla MT, Lleonart Bellfill R. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. Med Clin (Barc). 2020;155(10):448-453. https://doi.org/10.1016/j.medcli.2020.06.019. DOI: https://doi.org/10.1016/j.medcle.2020.06.026
Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84(2):390-397. https://doi.org/10.1016/j.jaad.2020.08.122. DOI: https://doi.org/10.1016/j.jaad.2020.08.122
Torres-Navarro I, Briz-Redón Á, Botella-Estrada R. Systemic therapies for Stevens-Johnson Syndrome and toxic epidermal necrolysis: a SCORTEN-based systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(1):159-171. https://doi.org/10.1111/jdv.16685. DOI: https://doi.org/10.1111/jdv.16685
Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21(3):307-311. https://doi.org/10.1007/s40257-020-00514-2. DOI: https://doi.org/10.1007/s40257-020-00514-2
Martínez-López A, Cuenca-Barrales C, Montero-Vilchez T, et al. Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: a guide for the dermatologist. J Am Acad Dermatol. 2020;83(6):1738-1748. https://doi.org/10.1016/j.jaad.2020.08.006. DOI: https://doi.org/10.1016/j.jaad.2020.08.006
Zhang J, Lei Z, Xu C, et al. Current perspectives on severe drug eruption. Clin Rev Allergy Immunol. 2021;61(3):282-298. https://doi.org/10.1007/s12016-021-08859-0. DOI: https://doi.org/10.1007/s12016-021-08859-0
Guzmán Perera MG, Vázquez P, David E. Manifestaciones misceláneas de COVID-19. Acta Méd Grupo Ángeles. 2021;19(s1):s42-s47. https://doi.org/10.35366/101027. DOI: https://doi.org/10.35366/101027
Khosravi M. A Possible type IV hypersensitivity reaction to older antiepileptic drugs during and after recovery from COVID-19 infection. Pharmacopsychiatry. 2022;55(1):58-59. https://doi.org/10.1055/a-1678-7429. DOI: https://doi.org/10.1055/a-1678-7429
Quintero Bustos G, Saeb Lima M. SARS-CoV-2: un mosaico clínico e histopatológico en la dermatología. Acta Méd Grupo Ángeles. 2021;19(s1):s58-s63. https://doi.org/10.35366/101029. DOI: https://doi.org/10.35366/101029